title: Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.
abstract: The growing list of available therapies for patients with multiple myeloma has resulted in tremendously high response rates and prolonged survival. However, the cure remains elusive. A continued effort at developing strategies to utilize all available treatment modalities in the most effective manner is needed. Allogeneic hematopoietic cell transplantation (allo-HCT) is a robust platform, associated with high response rates, and provides a unique foundation on which immune therapies and novel agents can be employed to improve clinical outcomes. Patients with high-risk myeloma and those relapsing after novel agent-based therapies or early after an autologous HCT should be considered for allo-HCT, ideally in a clinical trial setting. Results from several ongoing studies are expected to provide important information that will help determine the place of allo-HCT in the myeloma treatment algorithm.
authors.affiliation: Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. qbashir@mdanderson.org.
authors.forename: Qaiser
authors.initials: Q
authors.lastname: Bashir
authors.affiliation: Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 77030, USA.
authors.forename: Muzaffar H
authors.initials: MH
authors.lastname: Qazilbash
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000209:etiology; D020350:Graft vs Tumor Effect / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D018365:Neoplasm, Residual / Q000473:pathology; D054340:Receptors, KIR / Q000378:metabolism; D019233:Retreatment; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
chemical_list: D054340:Receptors, KIR
keywords: Allo-HCT; Allogeneic hematopoietic cell transplantation; Autologous HCT; Multiple myeloma; Stem cell transplantation